Overview

Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
0
Participant gender:
Female
Summary
Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) / C(600mg). Evaluation of unexpected and serious adverse events. (E=Epirubicin; C =Cyclophosphamide)
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Epirubicin
Criteria
Inclusion Criteria:

- Pre- and postmenopausal female patients with histologically confirmed primary breast
cancer

Exclusion Criteria:

- Metastatic breast cancer, locally advanced or recurrent breast cancer, previous cancer
history